NCT01671332 2020-05-12
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
University of Wisconsin, Madison
Phase 2 Completed
Clinical Trials
8 trialsNCT01038752 2015-05-21
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
Optimum Therapeutics, LLC
Phase 2 Terminated
NCT00002639 2013-06-21
Suramin in Treating Patients With Recurrent Primary Brain Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006929 2013-06-04
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002652 2013-02-04
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002921 2012-10-05
S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
SWOG Cancer Research Network
Phase 2 Terminated
NCT00004073 2012-05-03
Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00001266 2008-03-04
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed